Similar articles

• Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.

  Di Prima A, Botticelli A, Scalzulli E, Colafigli G, Pepe S, Lisi C, Marchetti P, Martelli M, Foà R, Breccia M. Di Prima A, et al. Ann Hematol. 2021 Aug;100(8):2117-2119. doi: 10.1007/s00277-020-04236-7. Epub 2020 Aug 27. Ann Hematol. 2021. PMID: 32856142 No abstract available.
• Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use.

  Sauvage M, Tavitian S, Sibaud V, Boulinguez S, Pages-Laurent C, Lamant L, Tournier E, Recher C, Meyer N. Sauvage M, et al. Ann Dermatol Venereol. 2021 Jun;148(2):140-141. doi: 10.1016/j.annder.2020.10.018. Epub 2021 Jan 19. Ann Dermatol Venereol. 2021. PMID: 33478822 No abstract available.
• Skin Cancer after Ruxolitinib or Belumosudil.

  Cutler C. Cutler C. N Engl J Med. 2023 Sep 21;389(12):1154-1155. doi: 10.1056/NEJMc2309427. N Engl J Med. 2023. PMID: 37733324 No abstract available.
• Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

  Uribe P, Gonzalez S. Uribe P, et al. Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Pathol Res Pract. 2011. PMID: 21531084 Review.
• Medical management of cutaneous malignancies.

  Gibbs P, Gonzalez R, Lee LA, Walsh P. Gibbs P, et al. Clin Dermatol. 2001 May-Jun;19(3):298-304. doi: 10.1016/s0738-081x(01)00173-0. Clin Dermatol. 2001. PMID: 11479042 Review. No abstract available.